logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Inc. (CNAT) Is Rising On Phase 2 Study Results

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Tuesday that its Phase 2 Liver Cirrhosis clinical trial showed a statistically significant reduction in caspase-cleaved cytokeratin 18 vs. placebo. Multiple additional liver disease biomarkers achieved statistically significant reductions vs. placebo. The stock is now up 0.41 on 655K shares.

Conatus Pharmaceuticals traded in a range for the bulk of Tuesday's session and closed down by 0.06 at $2.87.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT